评估狼疮低疾病活动状态中指南对齐的泼尼松阈值与损伤累积的关联
本研究纳入332例系统性红斑狼疮(SLE)患者(含105例新发病例),比较泼尼松等效剂量≤5 mg/天(LLDAS-5)与≤7.5 mg/天(LLDAS-7.5)的狼疮低疾病活动状态(LLDAS)定义与损伤累积的关联。结果显示,LLDAS-5持续时间越长与更少损伤累积稳健相关,但多变量调整后其相对LLDAS-7.5的增量预后价值未持续显现。
要点
- LLDAS-5持续时间越长与SLE患者损伤累积减少稳健相关。
- crude分析中LLDAS-5关联数值上更强,但多变量调整后优势未持续。
- LLDAS-5可作为临床有意义的指南对齐治疗目标。
核心结论
- LLDAS-5持续时间越长与更少损伤累积稳健相关,支持其作为临床有意义的指南对齐目标。
- LLDAS-5相对传统LLDAS-7.5的增量预后价值需进一步研究。
研究设计与样本
- 分析332例SLE患者,包括105例新发病例。
- 计算每例患者每年SDI恶化次数及处于LLDAS-5和LLDAS-7.5的平均随访时间比例。
- 采用患者水平Poisson回归,以随访年数为暴露,使用Huber稳健方差估计率比(RR)。
- 全队列多变量模型调整年龄、性别、 ethnicity、SLE病程、基线SLEDAI-2K和基线SDI。
主要发现
- 全队列中142/332例患者至少发生一次SDI增加(共190次)。
- LLDAS-5的粗RR为0.61(95%CI 0.37-1.00;p=0.052),LLDAS-7.5的粗RR为0.73(95%CI 0.39-1.37;p=0.332)。
- 多变量RR分别为LLDAS-5 0.56(95%CI 0.37-0.86;p=0.007)和LLDAS-7.5 0.47(95%CI 0.27-0.85;p=0.012),模型拟合相似。
- 新发病例中29/105例发生损伤(29次),LLDAS-5的RR为0.31(95%CI 0.11-0.89;p=0.029),LLDAS-7.5的RR为0.29(95%CI 0.09-0.93;p=0.036)。
关键数值与推荐
- LLDAS-5定义为泼尼松等效剂量≤5 mg/天,LLDAS-7.5定义为≤7.5 mg/天。
临床怎么用
- 可将LLDAS-5作为SLE临床有意义的治疗目标,强调泼尼松等效剂量≤5 mg/天。
- 传统LLDAS-7.5仍与较低损伤累积相关,LLDAS-5的增量预后价值需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether a modified Lupus Low Disease Activity State with a prednisone-equivalent threshold ≤5 mg/day (LLDAS-5) is more strongly associated with lower damage accrual than conventional LLDAS using a ≤7.5 mg/day threshold (LLDAS-7.5) in systemic lupus erythematosus (SLE). METHODS: We analysed 332 patients, including 105 incident cases. For each patient, yearly Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) worsening occasions and average proportion of follow-up spent in LLDAS-5 and LLDAS-7.5 were derived. Patient-level Poisson regression with follow-up years as the exposure and Huber's robust variance estimator estimated rate ratios (RRs). Parallel models were fitted for the two definitions. Full-cohort multivariable models adjusted for age, sex, ethnicity, SLE duration, baseline Systemic Lupus Erythematosus Disease Activity Index 2000 and baseline SDI. RESULTS: In the full cohort, 142/332 patients experienced at least one SDI increase (190 occasions). Crude RRs were 0.61 (95% CI 0.37 to 1.00; p=0.052) for LLDAS-5 and 0.73 (95% CI 0.39 to 1.37; p=0.332) for LLDAS-7.5. Multivariable RRs were 0.56 (95% CI 0.37 to 0.86; p=0.007) and 0.47 (95% CI 0.27 to 0.85; p=0.012), respectively, with similar model fit. Among incident cases, 29/105 patients accrued damage (29 occasions); both LLDAS-5 (RR 0.31, 95% CI 0.11 to 0.89; p=0.029) and LLDAS-7.5 (RR 0.29, 95% CI 0.09 to 0.93; p=0.036) were associated with lower damage accrual. CONCLUSION: Longer time in LLDAS-5 was robustly associated with less damage accrual. Crude full-cohort analyses suggested a numerically stronger inverse association and slightly better model fit for LLDAS-5, but this apparent advantage was not sustained after multivariable adjustment. These findings support LLDAS-5 as a clinically meaningful, guideline-aligned target, while its incremental prognostic value over conventional LLDAS-7.5 requires further study.
引用
- Parodis I, Andraos R, Bottai M, et al. Evaluating a guideline-aligned prednisone threshold within the Lupus Low Disease Activity State (LLDAS): associations with damage accrual. RMD Open. 2026. PMID: 42778332. doi:10.1136/rmdopen-2026-007162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。